Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations - PubMed (original) (raw)
Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations
D G Evans et al. J Med Genet. 1998 Jun.
Erratum in
- J Med Genet 1999 Jan;36(1):87
Abstract
Blood samples from 125 unrelated families with classical type 2 neurofibromatosis (NF2) with bilateral vestibular schwannomas have been analysed for mutations in the NF2 gene. A further 17 families fulfilling modified criteria for NF2 have also been analysed. Causative mutations have been identified in 54 (43%) classical families and six (35%) of those fulfilling modified criteria. Forty-two cases from 38 families with truncating mutations had an average age at onset of symptoms of 19 years and diagnosis at 22.4 years. Fifty-one cases from 16 families with splice site mutations (15 from six), missense mutations (18 from six), and large deletions (18 from five) had an average age of onset of 27.8 years and at diagnosis of 33.4 years. Subjects with truncating mutations were significantly more likely to have symptoms before 20 years of age (p<0.001) and to develop at least two symptomatic CNS tumours in addition to vestibular schwannoma before 30 years (p<0.001). There were also significantly fewer multigenerational families with truncating mutations. Four further truncating mutations were in mosaic form and were associated with milder disease than other similar mutations. This large study has confirmed the previous impression that truncating mutations are associated with severe disease, but caution has to be exercised in using mutation type to predict disease course.
Similar articles
- Identification of NF2 germ-line mutations and comparison with neurofibromatosis 2 phenotypes.
Kluwe L, Bayer S, Baser ME, Hazim W, Haase W, Fünsterer C, Mautner VF. Kluwe L, et al. Hum Genet. 1996 Nov;98(5):534-8. doi: 10.1007/s004390050255. Hum Genet. 1996. PMID: 8882871 - [Phenotype-genotype study in 154 French NF2 mutation carriers].
Demange L, De Moncuit C, Thomas G, Olschwang S. Demange L, et al. Rev Neurol (Paris). 2007 Nov;163(11):1031-8. doi: 10.1016/s0035-3787(07)74175-9. Rev Neurol (Paris). 2007. PMID: 18033041 French. - Clinical manifestations of mutations in the neurofibromatosis type 2 gene in vestibular schwannomas (acoustic neuromas).
Welling DB. Welling DB. Laryngoscope. 1998 Feb;108(2):178-89. doi: 10.1097/00005537-199802000-00005. Laryngoscope. 1998. PMID: 9473065 - A point mutation associated with a severe phenotype of neurofibromatosis 2.
MacCollin M, Braverman N, Viskochil D, Ruttledge M, Davis K, Ojemann R, Gusella J, Parry DM. MacCollin M, et al. Ann Neurol. 1996 Sep;40(3):440-5. doi: 10.1002/ana.410400313. Ann Neurol. 1996. PMID: 8797533 Review. - The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2.
Baser ME, Kuramoto L, Woods R, Joe H, Friedman JM, Wallace AJ, Ramsden RT, Olschwang S, Bijlsma E, Kalamarides M, Papi L, Kato R, Carroll J, Lázaro C, Joncourt F, Parry DM, Rouleau GA, Evans DG. Baser ME, et al. J Med Genet. 2005 Jul;42(7):540-6. doi: 10.1136/jmg.2004.029504. J Med Genet. 2005. PMID: 15994874 Free PMC article. Review.
Cited by
- Development of NF2 gene specific, strictly sequence defined diagnostic microarray for deletion detection.
Mantripragada KK, Buckley PG, Jarbo C, Menzel U, Dumanski JP. Mantripragada KK, et al. J Mol Med (Berl). 2003 Jul;81(7):443-51. doi: 10.1007/s00109-003-0458-3. Epub 2003 Jun 27. J Mol Med (Berl). 2003. PMID: 12830322 - The neurofibromatosis type 2 gene is mutated in perineurial cell tumors: a molecular genetic study of eight cases.
Lasota J, Fetsch JF, Wozniak A, Wasag B, Sciot R, Miettinen M. Lasota J, et al. Am J Pathol. 2001 Apr;158(4):1223-9. doi: 10.1016/S0002-9440(10)64072-2. Am J Pathol. 2001. PMID: 11290539 Free PMC article. - Management of neurofibromatosis type 2 and schwannomatosis associated peripheral and intraspinal schwannomas: influence of surgery, genetics, and localization.
Gugel I, Grimm F, Tatagiba M, Schuhmann MU, Zipfel J. Gugel I, et al. J Neurooncol. 2022 Sep;159(2):271-279. doi: 10.1007/s11060-022-04061-0. Epub 2022 Jun 30. J Neurooncol. 2022. PMID: 35771312 Free PMC article. - Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms.
Carroll SL. Carroll SL. Acta Neuropathol. 2012 Mar;123(3):321-48. doi: 10.1007/s00401-011-0928-6. Epub 2011 Dec 11. Acta Neuropathol. 2012. PMID: 22160322 Free PMC article. Review. - Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification.
Evans DG, Ramsden RT, Shenton A, Gokhale C, Bowers NL, Huson SM, Pichert G, Wallace A. Evans DG, et al. J Med Genet. 2007 Jul;44(7):424-8. doi: 10.1136/jmg.2006.047753. Epub 2007 Feb 16. J Med Genet. 2007. PMID: 17307835 Free PMC article.
References
- Hum Genet. 1995 Jun;95(6):712 - PubMed
- Hum Genet. 1995 May;95(5):572-4 - PubMed
- Neurosurgery. 1996 May;38(5):880-5; discussion 885-6 - PubMed
- Am J Hum Genet. 1996 Aug;59(2):331-42 - PubMed
- Am J Hum Genet. 1996 Sep;59(3):529-39 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
Miscellaneous